Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 second quarter operational and financial results after market close on Tuesday, February 3, 2026. The company will host a conference call and live webcast the same day at 4:30 p.m. Eastern time followed by a Q&A session.
Call-in numbers: (888) 506-0062 (U.S.) and +1 (973) 528-0011 (international) using participant access code 567381. The webcast will be available live and archived at the provided webcast link and on the Investors section of the company website under Events & Presentations. A teleconference replay will be available through February 17, 2026 at (877) 481-4010 (U.S.) or +1 (919) 882-2331 (international) using replay access code 53322.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AYTU gained 0.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AYTU was up 0.74% while peers showed mixed moves: TXMD up 6.13%, GELS down 7.06%, FLGC down 2.06%, and IXHL down 2.5%. This points to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Investor Day recap | Positive | -2.6% | Recap of Investor Day focused on EXXUA Phase 3 data and opportunity. |
| Jan 20 | Product launch | Positive | +0.8% | Nationwide launch of EXXUA for major depressive disorder in adults. |
| Jan 13 | Conference participation | Positive | +4.6% | CEO fireside chat at Lytham Partners 2026 Investor Healthcare Summit. |
| Jan 12 | Investor Day agenda | Neutral | +1.5% | Details on planned EXXUA‑focused Investor Day presentations and webcast. |
| Dec 18 | Investor Day announcement | Positive | -3.9% | Announcement of January 20, 2026 Investor Day centered on EXXUA. |
Recent news has centered on EXXUA’s launch and investor outreach, with market reactions mixed and sometimes selling pressure following otherwise positive updates.
Over the last several months, AYTU has focused investor communications on EXXUA, including an Investor Day on January 20, 2026, launch-related highlights the same day, and multiple announcements about that Investor Day starting on December 18, 2025. The company also participated in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. Price reactions to these events have varied, with both positive and negative moves following EXXUA‑focused news and investor outreach.
Market Pulse Summary
This announcement schedules AYTU’s fiscal 2026 second‑quarter results and conference call on February 3, 2026, continuing the company’s pattern of structured investor communication around EXXUA and broader operations. Recent history shows mixed price reactions to seemingly positive news, underlining that the substance of reported revenue, profitability, and commercialization progress will matter more than the timing. Investors may focus on how Q2 numbers compare with prior filings and recent launch‑related milestones.
AI-generated analysis. Not financial advice.
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 567381.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53322, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until February 17, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53322.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Aytu BioPharma (AYTU) report fiscal 2026 Q2 results?
What time is the Aytu BioPharma (AYTU) earnings conference call on February 3, 2026?
How can U.S. investors join the Aytu (AYTU) call on February 3, 2026?
Where is the Aytu (AYTU) webcast for the February 3, 2026 results available?
How long is the replay available for Aytu (AYTU) February 3, 2026 call and how to access it?
Will Aytu BioPharma (AYTU) include a Q&A during its February 3, 2026 results call?
